Collaborative Research Laboratory

Department of Electronic Health Record Department of Structural Bioscience for Taste Molecular Recognition
Alliance Laboratory for Advanced Medical Research Department of Drug Discovery for Lung Diseases
Translational Research Department for Skin and Brain Diseases Department of Medical Intelligent Systems
Department of Preventive Physical Therapy Department of Immunosenescence
Department of Advanced Medicine for Respiratory Failure Department of Clinical Bio-resource Research and Development
Department of Regulation of Neurocognitive Disorders Department of Pain Pharmacogenetics
Department of Epilepsy, Movement Disorders and Physiology

Department of Electronic Health Record

– Expansion of the frontier of Electronic Health Record (EHR) –
Current information science leads a new era, which provides new knowledge with massive data stream analysis. To extend the possibility of treatment and clinical study outcome, infrastructure of medical information should mediate information sources beyond the border between health and disease.
The EHR Research Unit aims to achieve personalized healthcare information infrastructure by research collaboration with multiple domain companies; information technology (IT) service consultation, medicine manufacture, laboratory testing services, and care services.
Electronic Health Record(EHR) study consists of standardization, massive data access technology, massive data analysis, medical and health care collaboration support, secondary use of medical information such as clinical study, legal validity issue, and so on.
Therefore, several research topics, which are fundamental to social installation of an EHR, are listed to each collaborative company.
Social design and installation are also promoted by collaboration with NPO, which is an alliance of EHR researchers.
Recently, nationwide EHR establishment are promoted by government in several countries.
Also, Japanese government realized that the necessity of nationwide EHR to incuvate various medical business.
In these circumstances, our lab performs research and education collabollation with international commuity openEHR, and students, such as Thailand, Philippines, Lebanon, and Grenada.

Associate Professor: Naoto Kume
Emeritus Professor: Hiroyuki Yoshihara

GlaxoSmithKline K.K.
NTT DATA Corporation
SRL, Inc.
RadianceWare Inc.

・Department of EHR:

Department of Structural Bioscience for Taste Molecular Recognition

Under construction

Alliance Laboratory for Advanced Medical Research (Alliance Station)
-Collaboration Framework for Drug Discovery Research with Astellas-

There are still many unmet medical needs in the world including those of intractable diseases and rare diseases. Due to their complexity and rarity, mechanisms of these diseases are more difficult to be clarified, and drug discovery for these diseases requires an understanding of disease pathologies in humans. Thus, researches using blood and other clinical samples to identify molecules and cells critically associated with patients’ diseases, and those determining patient stratification are being highly demanded. In order to exploit findings of these studies and deliver innovative drugs to patients as soon as possible, efficient and in-depth research collaborations between academia and pharmaceutical company are needed in situations close to the clinical setting and diseases.
To further accelerate drug discovery research through evolution of the open innovation system of the AK Project*, where, clinical and basic research of the university and drug discovery research of the company are closely linked in a timely manner, Kyoto University and Astellas established Alliance Station (A-Station), a new open innovation scheme at Kyoto University, and the Alliance Laboratory for Advanced Medical Research as a framework for the implementation of its activities. A-Station is a new platform for collaboration between industry and academia and under this scheme, Kyoto University and Astellas will conduct joint research projects in all therapeutic areas in a prompt and flexible manner.Director:Shuh Narumiya(Professor, Graduate school of Medicine)
Industrial Partner:Astellas Pharma Inc.* AK Project: Collaborative research conducted by Kyoto University and Astellas from July 2007 to March 2017 in “Center for Innovation in Immunoregulative Technologies and Therapeutics” as a “Creation of Innovation Centers for Advanced Interdisciplinaly Resarch Areas Prgram” funded by the the Ministry of Education, Culture, Sports, Science and Technology.

Department of Drug Discovery for Lung Diseases

In the era of an aging society, lung diseases such as pulmonary fibrosis, lung cancer, COPD, bronchial asthma and pneumonia have an increasing impact on healthy life expectancy. Although more than two trillion yen is spent for lung diseases each year in Japan, the therapeutic agents for lung diseases are still limited. We think that one of the reasons is the complexity of human lung structure, consisting of various cells and matrices forming numerous tracheal branches and >300 million alveoli with elaborate network of blood vessels. However, the recent progress in human lung cell biology has made it possible to initiate this project of drug discovery for refractory lung diseases under the collaboration of academic and industrial researchers in Kyoto University.

Translational Research Department for Skin and Brain Diseases

Our aim is development of new drugs for diseases of skin and central nervous system (CNS). To realize it, basic researchers and clinical experts work together in cooperation with industrial scientists. Atopic dermatitis is one of the diseases targeted in the dermatology area, and more than 400,000 patients suffer atopic dermatitis in Japan. Although the mainstream of treatment is immunosuppressive agents such as topical corticosteroids or tacrolimus ointment, the therapeutic effects are insufficient in many cases. Therefore, development of new drugs for atopic dermatitis has been waited for. In this department, we will develop new drugs targeting itching. In the area of ​​the CNS, we will try to develop novel drugs against CNS diseases such as Alzheimer’s disease, chronic fatigue syndrome, and pain syndrome, for which we do not have any satisfactory treatment now. We believe we can develop novel therapeutic agents to control disease progression and improve symptoms by modifying neurotransmitter functions.
For compounds fully analyzed and demonstrated to be effective, we promptly conduct clinical trials. Our goal is to deliver new drugs for patients.

Department of Medical Intelligent Systems

With rapid advances in scientific technology, the digitalization of medical front lines continues to progress, and a wide range of medical information (real world data) is being accumulated. It is strongly anticipated that this trend will bring about advanced, next-generation medical care that will deliver optimal care to patients, stemming/resulting from the combination of this data with revolutionary advances in AI to evaluate and analyze medical information, while applying it to the actual clinical front lines.
Currently, AI has already demonstrated an impressive ability to evaluate and analyze certain types of medical images. At the same time, to build AI that can make more sophisticated determinations, it is necessary to use detailed clinical time series data. Much of this data, however, consists of unstructured information, such as notes written by medical personnel. Moreover, there is not yet any AI technology that, in a practical application, can integrate and link together the huge volumes of various types of data, such as the text and figures in electronic medical records, reports in medical journals, genomic data, and diagnostic images. To put this data to use, it has become essential to develop AI for medicine through the close collaboration of researchers with a high degree of knowledge of the medical field with AI researchers and engineers.
Our research will use a wide range of different and highly sophisticated medical data, including Patient data collected on the electronic medical records of Kyoto University Hospital. By using AI to analyze these large volumes of advanced medical data that have been accumulated on the front lines of medicine, Kyoto University and Fujitsu expect to not only improve the quality of medical care, but also to discover new treatments and diagnostic methods. This joint research project will not be limited to just evaluating technology, but through the use of real data, will also create genuinely effective and useful knowledge, giving back meaningful results to society.
Associate Professor: Yoshinori Tamada
Assistant Professor: Eiichiro UchinoCollaboration:
Fujitsu Ltd.
Fujitsu Laboratories Ltd.

Department of Preventive Physical Therapy

Intervention based on physical therapy has been proven to be effective for various disabilities. However, to extend healthy lifespan in a super-aged society, it is important not only to intervene after deterioration or disability of motor and cognitive functions, but also to prevent them from occurring.
The aim of Department of Preventive Physical Therapy is to verify the effect of exercise programs based on physical therapy for disability prevention through collaboration research with SmartHealth, Inc.
Within this multi-organization department, SmartHealth, Inc. develops facilities (workout gym), health care applications, and a PHR (Personal Health Record) database of service users. Kyoto University develops new exercise programs based on physical therapy (multicomponent exercise) and new methods of evaluating motor and cognitive function using cutting-edge technology. Together we also verify the effect of the program at the gym and the home program delivered by the application.
We are planning to tackle healthy lifespan expectancy in Japan with a multilateral approach through collaboration between academia and industry.Staff:
Associate Professor: Hiroshige Tateuchi
Assistant Professor: Megumi OtaCollaboration:
SmartHealth, Inc.
Website URL:

Department of Immunosenescence

A variety of chronic diseases such as diabetes, hyperlipidemia, chronic renal failure and rheumatoid arthritis as well as most tumors (cancer) occur frequently with age of individuals. These diseases are collectively referred to as age-related diseases. Age-associated changes in immunity, termed immunosenescence, have been considered to play a major role in their age-related incidence. Immunosenescence is characterized by attenuation of infection resistance due to declining acquired immune function, the breakdown of self-tolerance and increased risk of autoimmune disease and gaining of a pro-inflammatory trait. However, exact mechanisms of immunosenescence have not yet been clarified. We will focus on the newly discovered senescence-associated T (SA-T) cells and elucidate the mechanisms of immune aging phenomena at the cellular and molecular level. Through these investigations, we will develop new ways of controlling immune aging for the treatment and prevention of age-related diseases such as chronic inflammatory diseases and cancer which are becoming increasingly important medical problems in the progress of aging society.

Professor:Masakazu Hattori
Assistant Professor:Yuji Fukushima

Department of Advanced Medicine for Respiratory Failure

Respiratory failure is caused by various conditions, including the impairment of gas exchange due to lung injury, pump failure of respiratory muscles, and abnormal ventilatory control. Respiratory failure is an important disease condition, because it can impair healthy life expectancy. In addition to drugs, respiratory rehabilitation, and surgeries such as lung transplantation, chronic respiratory failure treatment includes oxygen therapy and noninvasive ventilation (NIV).
Home health care, including home oxygen therapy (HOT), is an important part of chronic respiratory failure treatment. The number of patients on HOT has increased steadily to 140,000 in 2014, and the primary users are elderly patients with an average age >70 years. This trend will likely continue because Japan is experiencing a “super-aging” society.
The development of telecommunications equipment has enabled us to establish telemedicine, including telemonitoring. Telemonitoing has attracted interest as a potential solution to provide care for increasing aging populations living with chronic respiratory failure, particularly HOT users. In Japan, payment for “remote patient monitoring” was newly added to the medical payment system in 2018. Despite the increasing importance of home health care and telemedicine for chronic respiratory failure, a system to collect useful bioinformation has not yet been established. The aim of this department is to improve the management of respiratory failure by establishing a telemonitoring system through the collaboration of the Kyoto University Hospital and Teijin Pharma Ltd.Staff:
Associate Professor: Tomohiro Handa
Assistant Professor: Satoshi HamadaCollaboration:Teijin Pharma Ltd

Department of Clinical Bio-resource Research and Development

For medical research and development, clinical samples are emerging to play important roles in every phase throughout the entire process. Moreover, clinical sample is one of the most valuable resources for assessing interpatient heterogeneity to achieve precision and personalized medicine. Thus, analysis on clinical samples become more and more critical for clinical practice as well as R&D. Kyoto university has built up KBBM, Inc. teaming up with 7 private companies to ensure ethics and quality in collection, transfer and preservation of clinical samples. These supports by KBBM are going to be applied to all the clinical samples and medical information associated with them, including healthy controls, collected through the Clinical Bioresource Center in Kyoto university hospital. Accordingly, medical research and development in Kyoto university will be further promoted by taking advantages of easily accessible and quality controlled clinical samples and their data.
The researchers in our department have developed and improved methods for the preparation, culture and application of cancer cells as well as normal cells from patient samples. We are currently working on establishing panels of the cultured cancer cells from different patient samples. By integrating information including ex vivo chemo/radio-sensitivity assay, in vivo assay, clinical course, genome sequencing, OMICS data, and so on, we aim to develop novel targets of therapy, and biomarkers for selecting suitable therapeutics for each patient. We keep promoting innovation in the technology of culturing patient-originated cells to truly realize personalized medicine.

Program specific professor:Masahiro Inoue
Program specific assistant professor:Jumpei Kondo

Department of Regulation of Neurocognitive Disorders

Department of Regulation of Neurocognitive Disorders
– Alliance between Japanese-founded U.S. Bio Ventures (Cyn-K, LLC & VLP Therapeutics, LLC) and Department of Neurology of Kyoto University Graduate School of Medicine –
As Japan entered a rapidly aging society and the number of people with neurocognitive disorders continues to increase, finding measures to address them has become urgent matters for the whole country. In particular, patients with neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are increasing in number depending on the age, however there is still no fundamental treatment for such neurocognitive disorders.In our department, we will use the platform technology discovered and developed by VLP
Therapeutics (USA), co-founded by our industry collaborator, and investigate the effects of the
vaccine targeting a pathogenesis protein associated with neurocognitive disorders on such
disorders, as well as elucidate the mechanism of brain degeneration and aging.We think it better to have vaccines for the treatment of neurocognitive disorders. They offer not only economic advantage but also objective indexes such as antibody titers that can be used to measure the effects. Furthermore, they eliminate the concerns for elderly patients with neurocognitive disorders to forget to medicate or to over-medicate themselves. Vaccines offer overwhelming benefits over drugs that need to be taken daily, or the expensive antibody medicines. We aim to develop three types of vaccines according to the progression of the disease.
Management Members:
Ryuji Ueno, M.D., Ph.D., Ph.D., Professor, Department of Regulation of Neurocognitive Disorders
Ryosuke Takahashi, M.D., Ph.D., Professor and Chairman, Department of Neurology
Wataru Akahata, Ph.D., Associate Professor, Regulation of Neurocognitive Disorders
Akira Kuzuya, M.D., Ph.D., Associate Professor, Department of Neurology
Yasuto Tanabe, M.D., Ph.D., Associate Professor, Department of Regulation of Neurocognitive Disorders
Kazuya Goto, M.D., Ph.D., Assistant Professor, Department of Regulation of Neurocognitive Disorders

Department of Pain Pharmacogenetics

Genetic variations in nociceptor voltage-gated sodium ion channels have recently been associated with neuronal excitation and various pain-related diseases. Elucidation of the mechanisms by which mutations in these channels sensitize or desensitize individuals to pain provides novel strategies for the development of new and effective non-opioid analgesics.
We discovered that chronic childhood limb pain can partly be attributed to mutations in the SCN11A gene (p.R222H or p.R222S), which encodes the Nav1.9 voltage-gated sodium ion channel. We termed this chronic limb pain syndrome as “四肢疼痛発作症” in Japanese (Okuda et al., PLOS One 2016), and subsequently founded the Department of Pain Pharmacogenetics to clarify this pathological condition in detail and to use this model in the development of safe and effective pain therapeutics.
Main Research Activities
1. Investigation of the pathophysiology of childhood limb pain attack, and the efficacy of candidate therapeutic drugs
a) Examination of the Nav1.9 channel properties of dorsal root ganglia isolated from pain model mice carrying SCN11A mutations (p.R222S, F814C, or F1146S).
b) Evaluation of the effects and mechanisms of action of candidate Nav1.9 inhibitors and pain therapeutics developed by AlphaNavi Pharma Inc., using our pain model mice.
2. Epidemiological survey of families with suspected limb pain attack
a) Epidemiological investigation to clarify the national distribution of childhood limb pain attack, and construction of a nationwide registry.
b) Analysis of pain-related genetic variants in families with childhood limb pain attack symptoms.

Faculty of Department of Pain Pharmacogenetics:
Professor: Shohab Youssefian
Associate Professor: Hiroko Okuda
Assistant Professor: Aya Takeya
Research Fellow: Akio Koizumi
Research Fellow: Yoshihiro Oyamada
TEL: 075-753-9295
Collaboration: AlphaNavi Pharma Inc.

Department of Epilepsy, Movement Disorders and Physiology

Department of Epilepsy, Movement Disorders and Physiology was established as an Endowed Department in August 2013, supported by the Department of Neurology (chaired by Prof. Ryosuke Takahashi), and has been continuing as the Industry-Academia Collaboration Course since June 2018. We keep working on clinical research to solve pathomechanism of epilepsy and movement disorders, developments of new treatments from the aspect of neurons and glia, and translatable and translational research under close collaboration with basic scientists. We also provide a wide range of educational opportunities to physicians and clinical researchers internationally.
1) We started joint clinical researches (with Eisai Co., Ltd.) to elucidate the property of paroxysmal depolarization shift (PDS) at epileptic foci in human and to individualize inhibitory mechanism of anti-epileptic/seizure drugs which have direct and/or indirect effects on PDS, such as AMPA antagonist. We also aim to elucidate pathomechanism of neurological disorders in which neurons and glia underly, and develop the precisional treatments.
The followings are our continuous activities since 2013 of establishment (supported by NIHON KOHDEN, Otsuka Pharmaceutical., and UCB Japan).
2) Clinical activities and education
We aim to solve pathophysiology of epilepsy and movement disorders, and to develop new treatments that could lead to the advanced medical care. We also aim at standardizing it in clinical practice. We provide integrated teaching opportunities for training of physician-scientists, clinical specialists, and leaders of related fields internationally.
3) Research activities
We promote clinical practice and research of clinical neurophysiology on epilepsy and movement disorders and its clinical application, which are very closely related to neurophysiological knowledge and methods.
Hypothesis of active vs. passive DC shift in the ictal period.
We hypothesize that DC shifts in chronic epilepsy reflect an active process caused by astrocyte dysfunction (active DC shift) preceding ictal high frequency oscillations (HFOs), which is different from acute symptomatic seizures where DC shifts would just be the consequence of high neuronal activity (passive DC shift). (cited from Ikeda A, et al. Neurosci Res. 2020;156:95-101.)
Professor: Akio Ikeda, M.D., Ph.D., FACNS
Associate Professor: Masao Matsuhashi, M.D., Ph.D.
Assistant Professor: Kiyohide Usami, M.D., Ph.D.
Tel: +81-75-751-3662